In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:
- Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
- Evaluating the future impact of key items when reviewing a biotech IP portfolio
- Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
- Valuation methodologies used for early-stage vs. late-stage products
Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.
Related Insights
July 28, 2025
Tariff & International Trade Resource
FinCEN Exercises New Authority Targeting Mexico-Based Financial Institutions to Counter Cartel-Linked Fentanyl Trade
On June 25, 2025, the Financial Crimes Enforcement Network at the U.S. Department of the Treasury designated three Mexico-based financial institutions as primary money laundering concerns under Section 311 of the USA PATRIOT Act.
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…